6 completed, 1 active not recruiting, 1 terminated. 8 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 6, Active not recruiting 1, Terminated 1 |
| Phase 1 | 4 | Completed 4 |
Follow 1-methyltryptophan: new trials by email Literature Review of 1-methyltryptophan trials Research Report on 1-methyltryptophan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG Indoximod, Partial Radiation, Full-dose Radiation - Glioblastoma, Medulloblastoma | Phase 2 | Active not recruiting | Theodore S. Johnson | 130 | 2019-10-02 | 2026-01-08 |
| A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma Pembrolizumab, Nivolumab, Indoximod - Melanoma | Phase 2 | Terminated | NewLink Genetics Corporation | 21 | 2017-12-08 | 2022-09-27 |
| Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer Nab-Paclitaxel, Gemcitabine, Indoximod - Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Completed | NewLink Genetics Corporation | 157 | 2014-08-01 | 2026-04-03 |
| Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma Indoximod, Ipilimumab, Nivolumab - Metastatic Melanoma, Stage III Melanoma | Phase 1 / Phase 2 | Completed | NewLink Genetics Corporation | 131 | 2014-07-01 | 2026-05-29 |
| Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors Indoximod, Temozolomide, Bevacizumab - Glioblastoma Multiforme, Glioma | Phase 1 / Phase 2 | Completed | NewLink Genetics Corporation | 160 | 2014-03-01 | 2024-03-27 |
| Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer Docetaxel, Placebo, Indoximod - Metastatic Breast Cancer | Phase 2 | Completed | NewLink Genetics Corporation | 169 | 2013-02-01 | 2020-05-28 |
| Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer Indoximod, Sipuleucel-T, Placebo - Metastatic Prostate Cancer | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 47 | 2012-10-01 | 2020-04-03 |
| Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer adenovirus-p53 transduced dendritic cell (DC) vaccine, 1-methyl-d-tryptophan, Laboratory biomarker analysis - Male Breast Cancer, Recurrent Breast Cancer | Phase 1 / Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 44 | 2009-12-28 | 2018-04-11 |
Brain Neoplasms (2) · Breast Neoplasms (2) · Glioblastoma (2) · Melanoma (2) · Adenocarcinoma (1) · Breast Neoplasms, Male (1) · Diffuse Intrinsic Pontine Glioma (1) · Ependymoma (1) · Glioma (1) · Gliosarcoma (1) · Medulloblastoma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1)
NewLink Genetics Corporation (5) · H. Lee Moffitt Cancer Center and Research Institute (1) · Masonic Cancer Center, University of Minnesota (1) · Theodore S. Johnson (1)
United States (8) · Poland (1)
Hatem Soliman (1) · Shilpa Gupta, M.D. (1) · Theodore S Johnson, MD, PhD (1)
P30CA076292 (1), R01CA229646 (1)